Quantcast
Home > Quotes > BPMC
x
BPMC

Blueprint Medicines Corporation Common Stock (BPMC) Quote & Summary Data

$69.35
*  
1.27
1.8%
Get BPMC Alerts
*Delayed - data as of Oct. 18, 2018 13:04 ET  -  Find a broker to begin trading BPMC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    BPMC Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 69.28 / $ 69.59
1 Year Target
101
Today's High / Low
$ 70.47 / $ 68.67
Share Volume
69,017
50 Day Avg. Daily Volume
284,610
Previous Close
$ 70.62
52 Week High / Low
$ 109 / $ 57.44
Market Cap
3,043,614,214
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -4.10
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.4

Intraday Chart

Shares Traded

Share Volume:
69,017
50 Day Avg. Daily Volume:
284,610

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.10

Trading Range

The current last sale of $69.35 is 20.73% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 70.47 $ 109
 Low: $ 68.67 $ 57.44

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on developing potentially transformational medicines to improve the lives of patients with genomically defined cancers and rare diseases. Our approach is to leverage our novel target discovery engine to systematically and reproducibly identify kinases that are drivers of diseases in genomically defined patient populations and to craft highly selective and potent drug candidates that may provide significant and durable clinical responses for patients without adequate treatment options. This integrated biology and chemistry approach enables us to identify, characterize and design drug candidates to inhibit novel kinase targets that have been difficult to selectively inhibit. By focusing on diseases in genomically defined patient populations, we believe that we will have a more efficient development path with a greater likelihood of success.  ... More ...  


Risk Grade

Where does BPMC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 70.25
Open Date:
Oct. 18, 2018
Close Price:
$ 70.62
Close Date:
Oct. 17, 2018

Consensus Recommendation

Analyst Info